PLD1-driven oncogenic secretion creates a therapeutic vulnerability in chromosome 3q-amplified NSCLC.

High PLD1 activity is essential for growth and metastasis in 3q-amplified NSCLC, with its enzymatic activity boosted by coamplified ARF-like GTPase 14.

• Why it matters: Therapeutic strategies targeting oncogenic drivers within chromosome 3q amplification have been unsuccessful, highlighting the need for new targets in this common NSCLC subtype.
• What they did: The study analyzed 3q-amplified NSCLC samples, revealing that PLD1 is highly expressed and catalyzes oncogenic lipid production, supporting tumor growth through secretion of oncogenic factors.
• The result: A TFRC antibody-drug conjugate with a PLD1 inhibitor showed potential antitumor activity in mouse models, suggesting PLD1-targeted therapies may offer a new treatment approach.